Evidence map›Paper›PMID 37813091›Full record

ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2024

Altered Gene Expression Within the Renin-Angiotensin System in Normal Aging and Dementia.

Hannah M Tayler, Robert MacLachlan, Özge Güzel, Robert A Fisher, Olivia A Skrobot, Mohamed A Abulfadl, Patrick G Kehoe, J Scott Miners

Open access · hybridAbstract read
In one paragraph

Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Distinct single-nucleus RNA-seq changes among non-neuronal cells in ADNC, LATE-NC, and mixed pathologies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
  3. Microglial activation and RAS signaling: a dual-edged sword in neuroinflammation.American journal of physiology. Regulatory, integrative and comparative physiology · 2026
    Review
  4. ACE2: Friend or Foe in Post-COVID-19 Neurodegeneration?International journal of molecular sciences · 2025
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hannah M TaylerDementia Research Group, Clinical Neurosciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0001-7157-6769
Robert MacLachlanDementia Research Group, Clinical Neurosciences, Bristol Medical School, University of Bristol, Bristol, UK.
Özge GüzelDementia Research Group, Clinical Neurosciences, Bristol Medical School, University of Bristol, Bristol, UK.
Robert A FisherDementia Research Group, Clinical Neurosciences, Bristol Medical School, University of Bristol, Bristol, UK.
Olivia A SkrobotDementia Research Group, Clinical Neurosciences, Bristol Medical School, University of Bristol, Bristol, UK.
Mohamed A AbulfadlDementia Research Group, Clinical Neurosciences, Bristol Medical School, University of Bristol, Bristol, UK.
Patrick G KehoeDementia Research Group, Clinical Neurosciences, Bristol Medical School, University of Bristol, Bristol, UK.
J Scott MinersDementia Research Group, Clinical Neurosciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0001-8594-1640
Southmead Hospital · GB

Funding

Alzheimer's Society Program Grant AS-PG-17b-004ARUK Senior Fellowship ARUK-SRF-2019A-001Medical Research Council.Sigmund Gestetner Foundation
6 · The paper itself

Abstract

The renin-angiotensin system (RAS) is dysregulated in Alzheimer's disease (AD). In this study, we have explored the hypothesis that an -age--related imbalance in brain RAS is a trigger for RAS dysregulation in AD. We characterized RAS gene expression in the frontal cortex from (i) a cohort of normal aging (n = 99, age range = 19-96 years) and (ii) a case-control cohort (n = 209) including AD (n = 66), mixed dementia (VaD + AD; n = 50), pure vascular dementia (VaD; n = 42), and age-matched controls (n = 51). The AD, mixed dementia, and age-matched controls were further stratified by Braak tangle stage (BS): BS0-II (n = 48), BSIII-IV (n = 44), and BSV-VI (n = 85). Gene expression was calculated by quantitative PCR (qPCR) for ACE1, AGTR1, AGTR2, ACE2, LNPEP, and MAS1 using the 2-∆∆Cq method, after adjustment for reference genes (RPL13 and UBE2D2) and cell-specific calibrator genes (NEUN, GFAP, PECAM). ACE1 and AGTR1, markers of classical RAS signaling, and AGTR2 gene expression were elevated in normal aging and gene expression in markers of protective downstream regulatory RAS signaling, including ACE2, MAS1, and LNPEP, were unchanged. In AD and mixed dementia, AGTR1 and AGTR2 gene expression were elevated in BSIII-IV and BSV-VI, respectively. MAS1 gene expression was reduced at BSV-VI and was inversely related to parenchymal Aβ and tau load. LNPEP gene expression was specifically elevated in VaD. These data provide novel insights into RAS signaling in normal aging and dementia.

Indexed as

Alzheimer DiseaseMixed DementiasAgedAged, 80 and overAgingAngiotensin-Converting Enzyme 2Gene ExpressionHumansNeoplasm ProteinsPeptidyl-Dipeptidase ARenin-Angiotensin SystemRibosomal ProteinsAngiotensin-Converting Enzyme 2Neoplasm ProteinsPeptidyl-Dipeptidase ARibosomal ProteinsRPL13 protein, humanAngiotensin-converting enzyme (ACE)Angiotensin-II type 1 receptor (AGT1R)Angiotensin-II type 2 receptor (AGT2R)

Identifiers

PMID37813091
PMCPMC10733177
OpenAlexW4387445155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.